Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotics Need Additional Development Incentives, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Director Woodcock tells House panel that a guidance clarifying trial designs is not enough, an acknowledgement a Cubist executive calls a "break-through."

You may also be interested in...



Antibiotics Need "Societal Class" Designation To Improve Discovery, Discourage Use, Tufts Professor Tells Congress

As part of its effort to encourage the development and preservation of antibiotics, FDA should consider classifying them separately from other drugs, one scientist argued

Antibiotics Need "Societal Class" Designation To Improve Discovery, Discourage Use, Tufts Professor Tells Congress

As part of its effort to encourage the development and preservation of antibiotics, FDA should consider classifying them separately from other drugs, one scientist argued

Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus

Industry is questioning the fundamental statistical underpinnings of FDA's approval pathways for antibiotics even as the agency prepares to roll out several guidances to help clarify them

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel